News | May 02, 2026
Dr Lal PathLabs posts strong Q4 FY26 results with 16.6% revenue growth & PAT at Rs. 132 Cr
The company posted revenue of Rs. 703 crore in Q4 FY26
The company posted revenue of Rs. 703 crore in Q4 FY26
Leading orthopaedic experts call for equitable insurance coverage to patients for accessing advanced, precision-driven joint replacement technologies
On his visit to NIPER Mohali, union health minister vreviews biopharma research initiatives and calls for stronger industry collaboration and commercialization focus
Study introduces structured, condition-specific emergency coding system to improve coordination, response time, and patient safety in tertiary care hospitals
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations
The association is intended to strengthen healthcare delivery standards, particularly in Oncology services, and enhance patient care outcomes
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
The medtech firm strengthens its full-stack remote cardiac monitoring platform, achieves 11x revenue growth, and advances its global expansion plans
Landmark agreement opens market access, mobility pathways, and institutional collaboration for Ayurveda, Yoga, and holistic healthcare services
Subscribe To Our Newsletter & Stay Updated
